{"podcast":{"title":"Oncology Today with Dr Neil Love","slug":"oncology-today-with-dr-neil-love-1004241","podcast_index_feed_id":1004241,"rss_url":"https://feeds.captivate.fm/oncologytoday/","website_url":"https://www.researchtopractice.com","image_url":"https://artwork.captivate.fm/464a03b3-1b7f-4b39-a2c6-e3de4b1e77b7/8YAjpM6wBeZeb3Gyb3zbR3bE.jpg","author":"Dr. Neil Love","episode_count":463,"summary":"Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.","last_synced_at":"2026-07-28T06:21:37.419138+00:00","page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241"},"episode":{"title":"EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting","slug":"egfr-mutated-non-small-cell-lung-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting","published_at":"2026-07-21T13:00:00+00:00","page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/egfr-mutated-non-small-cell-lung-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting","show_page_url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241","url":"https://oncologytoday.captivate.fm/episode/6156-asco2026-egfrnsclc","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/40bd5afe-720d-4b0f-9273-180de9bd1c25.mp3","summary":"Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (00:00) Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27) EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08) Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16) Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08) Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46) CME information and select publications","meta_description":"Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, includ…","key_points":[],"chapters":[],"topics":[],"duration_seconds":7077,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/egfr-mutated-non-small-cell-lung-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/egfr-mutated-non-small-cell-lung-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}